CanCure Laboratories LLC Patent applications |
Patent application number | Title | Published |
20100137557 | USE OF ONE OR MORE METAL CARRIERS TO SELECTIVELY KILL MAMMALIAN CELLS - Compositions and methods for decreasing the viability of cells, particularly aberrant non-healthy cells, and most particularly cancer cells, are disclosed. The primary agent that causes cell death is a toxic metal atom or ion. Embodiments of the invention provide compositions and methods to ensure that the toxic metal is directed to the desired cell or tissue. In one embodiment, the metal is bound to a sulfur-rich peptide or protein carrier containing a targeting moiety. Such metal-protein complex is targeted to the selected cells or tissues to enrich the cell or tissue site with the metal-containing peptide or protein molecules followed by administering a dithiocarbonyl which carries the metal from the protein inside the cells to induce cell death. | 06-03-2010 |
20100048668 | COMPOSITIONS AND METHODS TO CONTROL ABNORMAL CELL GROWTH - A class of compounds commonly containing a trialkylammonium group have been synthesized and characterized as anticancer compounds. They can be used alone or in combination with other therapies to treat cancer and other cell proliferative diseases. Representative compounds of this class, N,N-diethyl-N-methyl-2-[(9-oxo-9H-thioxanthen-2-yl)methoxy]ethanaminium iodide and N,N-diethyl-N-allyl-3-(2-methyl-9H-thioxanthen-9-ylidene)-propane-1-aminium bromide, were shown in various tumor models to decrease tumor volume, enhance the effects of other chemotherapeutic agents including cisplatin, reduce chemotherapy-induced loss of body weight, and increase survival of animals co-treated with toxic amounts of cisplatin. These compounds had even greater effects on tumor volume, body weight, and survival when administered together with the human protein placental alkaline phosphatase. | 02-25-2010 |
20100022617 | COMPOSITIONS AND METHODS TO CONTROL ABNORMAL CELL GROWTH - A class of compounds commonly containing a trialkylammonium group have been synthesized and characterized as anticancer compounds. A representative of this class, N,N-diethyl-N-methyl-2-[(9-oxo-9H-thioxanthen-2-yl)methoxy]ethanaminium iodide (CCDTHT) was shown in various tumor models to decrease tumor volume, enhance the effects of other chemotherapeutic agents including cisplatin, reduce chemotherapy-induced loss of body weight, and increase survival of animals co-treated with toxic amounts of cisplatin. CCDTHT had even greater effects on tumor volume, body weight, and survival when administered to animals together with the human protein placental alkaline phosphatase. These trialkylammonium group-containing compounds and alkaline phosphatases, particularly in combination with each other and other therapies, may be used to treat cancer and other cell proliferative diseases. | 01-28-2010 |
20080207738 | DRUG COMBINATIONS TO TREAT DRUG RESISTANT TUMORS - Embodiments of the invention provide a method and composition for treating or reducing multiple drug resistance in cancers. Embodiments of the invention also provide for a xanthene compound to inhibit multidrug resistance protein 1. | 08-28-2008 |